Physician profile
Eric M Jackson
NPI 1346336443
$965.96
in general payments reported to CMS, 2019-2025
15 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $16.83 · 2021: $60.24 · 2022: $122 · 2023: $81.27 · 2024: $203 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $212.69 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $126.90 | 2024-2025 | Qelbree |
| Si-Bone, INC. | $110.19 | 2019 | |
| Sanofi Pasteur INC. | $102.07 | 2019-2025 | |
| Pfizer INC. | $85.45 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.54 | 2021-2022 | |
| Sobi, INC | $55.46 | 2019-2023 | |
| Glaxosmithkline, LLC. | $54.02 | 2020-2022 | |
| Corium, LLC | $38.61 | 2024-2025 | Azstarys |
| Astrazeneca Pharmaceuticals Lp | $35.85 | 2021-2024 | Flumist Quadrivalent |
| Verrica Pharmaceuticals INC. | $18.11 | 2024 | Ycanth |
| Ironshore Pharmaceuticals INC. | $16.50 | 2019 | |
| Neos Therapeutics, Lp | $15.65 | 2024 | Cotempla Xr-Odt |
| Sumitomo Pharma America, INC. | $15.57 | 2025 | Gemtesa |
| Cranial Technologies, INC | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.